Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Vfend approval

Executive Summary

Pfizer's Vfend receives supplemental approval for treatment of esophageal candidiasis Nov. 14. Vfend (voriconazole) was initially approved for primary invasive aspergillosis therapy in May 2002 (1"The Pink Sheet" June 3, 2002, p. 10)...

You may also be interested in...



Vfend dosing options expand

Oral suspension form of Pfizer's antifungal Vfend (voriconazole) receives FDA nod Dec. 9. Approval letter says Pfizer will conduct a "two-way drug interaction study between voriconazole and oral contraceptives." Dosage form joins tablets and injection (1"The Pink Sheet" Nov. 24, 2003, In Brief)...

Pfizer Vfend Antifungal Has Broader Indication, Doses Than Merck’s Cancidas

Pfizer's Vfend has a broader indication and more dosing options than Merck's Cancidas upon FDA approval of the Pfizer antifungal

Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty

The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel